Cas:135906-00-2 1-cyclohexyl-4-oxoquinoline-3-carboxylic acid manufacturer & supplier

Chemical Name:1-cyclohexyl-4-oxoquinoline-3-carboxylic acid

CAS.NO:135906-00-2

Synonyms:1-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Molecular Formula:C₁₆H₁₇NO₃

Molecular Weight:271.31100

HS Code:2933499090

Physical and Chemical Properties:

Melting point:237-238ºC

Boiling point:425.8ºC at 760 mmHg

Density:1.307g/cm3

Index of Refraction:1.627

PSA:59.30000

Exact Mass:271.12100

LogP:3.20490

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Use and application,1-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 1-cyclohexyl-4-oxoquinoline-3-carboxylic acid manufacturer Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself. 1-cyclohexyl-4-oxoquinoline-3-carboxylic acid supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-cyclohexyl-4-oxoquinoline-3-carboxylic acid vendor The Ministry of Agriculture said late Saturday that a fresh outbreak of a lethal form of influenza had been found in poultry in the southern province of Hunan, and that officials had ordered the slaughter of 17,828 chickens. 1-cyclohexyl-4-oxoquinoline-3-carboxylic acid factory Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.